These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

673 related items for PubMed ID: 31239245

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R.
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [Abstract] [Full Text] [Related]

  • 3. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T, Harada Y, Matsubara E, Suzuki T, Oyama T, Kasai M, Uchida T, Ogura M.
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [Abstract] [Full Text] [Related]

  • 4. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
    Neunert CE.
    Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ, Macahilig C, Grotzinger KM, Poston SA, Wang PF, Dawson KL, Ward M.
    Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
    [Abstract] [Full Text] [Related]

  • 7. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M, Kato M, Koh K, Hanada R.
    Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
    [Abstract] [Full Text] [Related]

  • 8. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K.
    Clin J Oncol Nurs; 2019 Apr 01; 23(2):212-216. PubMed ID: 30880797
    [Abstract] [Full Text] [Related]

  • 9. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
    Al-Samkari H, Kuter DJ.
    Br J Haematol; 2018 Oct 01; 183(2):168. PubMed ID: 29978577
    [No Abstract] [Full Text] [Related]

  • 10. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
    Lakhwani S, Perera M, Fernández-Fuertes F, Ríos de Paz MA, Torres M, Raya JM, Hernández MT.
    Eur J Haematol; 2017 Oct 01; 99(4):372-377. PubMed ID: 28759125
    [Abstract] [Full Text] [Related]

  • 11. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G, Palladino V, Vecchio GCD, Palmieri VV, Corallo PC, Faienza MF, Giordano P.
    Endocr Metab Immune Disord Drug Targets; 2021 Oct 01; 21(3):397-406. PubMed ID: 32473624
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S, Nakaseko C, Takeuchi M, Kumagai K, Komatsu T, Tanaka H, Hara S, Koizumi M, Imai H, Yokota A, Takeuchi M, Inokuchi K, Matsuura Y, Aotsuka N, Wakita H.
    Br J Haematol; 2013 Oct 01; 163(2):286-9. PubMed ID: 23862773
    [No Abstract] [Full Text] [Related]

  • 13. Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series.
    Poston JN, Gernsheimer TB.
    Int J Hematol; 2019 Aug 01; 110(2):255-259. PubMed ID: 30972617
    [Abstract] [Full Text] [Related]

  • 14. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G, Dolph M, Roy AN, Said Q, Forsythe A.
    Clin Ther; 2020 May 01; 42(5):860-872.e8. PubMed ID: 32199608
    [Abstract] [Full Text] [Related]

  • 15. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
    Zhang J, Liang Y, Ai Y, Xie J, Li Y, Zheng W.
    Expert Opin Pharmacother; 2017 Oct 01; 18(15):1543-1551. PubMed ID: 28845713
    [Abstract] [Full Text] [Related]

  • 16. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV, Vinogradova OY, Pankrashkina MM, Chernikov MV, Arshanskaya EG, Tkachenko NE.
    Ter Arkh; 2018 Aug 17; 90(7):70-76. PubMed ID: 30701925
    [Abstract] [Full Text] [Related]

  • 17. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
    González KJ, Zuluaga SO, DaRos CV, Rodríguez PP, Martí AC.
    Ann Hematol; 2017 Mar 17; 96(3):507-508. PubMed ID: 27975127
    [No Abstract] [Full Text] [Related]

  • 18. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
    Stasi R, Evangelista ML, Amadori S.
    Drugs; 2008 Mar 17; 68(7):901-12. PubMed ID: 18457458
    [Abstract] [Full Text] [Related]

  • 19. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
    Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF, Pediatric ITP Consortium of North America (ICON).
    Pediatr Blood Cancer; 2016 Aug 17; 63(8):1407-13. PubMed ID: 27135461
    [Abstract] [Full Text] [Related]

  • 20. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.
    Piccin A, Amaddii G, Natolino F, Billio A, Cortelazzo S.
    Blood Transfus; 2014 Jan 17; 12 Suppl 1(Suppl 1):s149-50. PubMed ID: 23736912
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.